Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY5R | Q15761 | 3/20 | 0.38 |
| ▸ | EDNRA | P25101 | 2/20 | 0.34 |
| ▸ | HTR6 | P50406 | 3/20 | 0.34 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | SGK1 | O00141 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835148 | 0.88 | TSHR (0.44) | EDNRAHTR6PTPN2PTPN1PTPN5 | |
| SCHEMBL4830890 | 0.84 | PKLR (0.42) | SGK1 | |
| SCHEMBL4833826 | 0.81 | HTR6 (0.41) | EDNRAHTR6SGK1 | |
| SCHEMBL4834414 | 0.80 | GFER (0.55) | — | |
| SCHEMBL4834620 | 0.79 | HSD11B1 (0.43) | EDNRAHTR6SGK1 | |
| SCHEMBL4833658 | 0.79 | PGR (0.43) | GHSRSGK1 | |
| SCHEMBL4825823 | 0.79 | PGR (0.42) | PTPN2PTPN1PTPN5SGK1 | |
| SCHEMBL4826272 | 0.78 | KMT2A (0.53) | PTPN2PTPN1PTPN5 | |
| SCHEMBL4834107 | 0.77 | ALDH1A1 (0.46) | EDNRA | |
| SCHEMBL4833946 | 0.76 | KEAP1 (0.46) | NPY5RHTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | claimed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | claimed |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | ADAMS JERRY LEROY | 2008-11-20 | — | — | US | disclosed |
| US-7427623-B2 | 4-Amino-2,3-disubstituted thieno[2,3-d]pyrimidines and pharmacetical compositions thereof | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-23 | — | — | US | disclosed |
| US-20050004142-A1 | Chemical compounds | SMITHKLINE BEECHAM CORPORATION | 2005-01-06 | — | — | US | disclosed |
| EP-1425284-A2 | FURO- AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003022852-A2 | FURO-AND THIENOPYRIMIDINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004142-A1 | Chemical compounds | TIE1, KDR, TEK | NPY5R 3227/4885EDNRA 266/4885HTR6 1473/4885 |
| US-20080287466-A1 | 4-AMINO-2,3-DISUBSTITUTED THIENO [2,3,D]PYRIMIDINES AND PHARMACEUTICAL COMPOSITIONS THEREOF | TIE1, TEK, KDR | NPY5R 1385/4885EDNRA 247/4885HTR6 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.